1 min read
1 min read

Small Molecule APIs: Aligning Drug Strategy with Partnering Strategy

Development of novel small molecule active pharmaceutical ingredients (APIs) is increasingly turned over to outsourced partners who have become the primary drivers of the product’s overall development and go-to-market strategy. With hundreds of potential partners that drug owners can choose from to develop and manufacture small molecule APIs, choosing the best partner can be a challenging task.

In this white paper, we explore the importance of purposefully aligning the overall drug development strategy with a partnering strategy. We also review how increasing development of novel drugs are also impacting the industry’s go-to-market efforts, driving new demand for expert small molecule API suppliers. Finally, we consider how small molecule API development projects can be executed by leveraging the experience of embedded contract development and manufacturing (CDMO) partners.

 

 

You can download the full white paper by completing the form below.

Pfizer CentreOne would like to send you information which we believe may be of value to you and relevant to your work. If you would like to receive such information, please tick the box below.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.